Genes, Chromosomes & Cancer最新文献

{"title":"Establishment and Characterization of a Novel Pleuropulmonary Blastoma Cell Line","authors":"Keisuke Kato,&nbsp;Hiroaki Goto,&nbsp;Mio Tanaka,&nbsp;Tetsuomi Suzuki,&nbsp;Yasunori Toyoda,&nbsp;Masato Shinkai,&nbsp;Norihiko Kitagawa,&nbsp;Toshiji Nishi,&nbsp;Hisato Kigasawa,&nbsp;Kenji Kurosawa,&nbsp;Noriko Aida,&nbsp;Ai Yoshimi,&nbsp;Asami Noda,&nbsp;Yumi Ito,&nbsp;Masafumi Seki,&nbsp;Junko Takita,&nbsp;Noriyuki Nagahara,&nbsp;Masahiro Tsuchida,&nbsp;Yukichi Tanaka","doi":"10.1002/gcc.23276","DOIUrl":"https://doi.org/10.1002/gcc.23276","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Pleuropulmonary blastoma (PPB) is an infrequently encountered childhood malignant intrathoracic neoplasm associated with unfavorable clinical behavior. Since a well-characterized preclinical model is essential for developing competent agents for PPB, we aim to establish and characterize the world's first cell line of PPB, and attempt to perform the cytotoxicity assay on the PPB cell line.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Experimental Design</h3>\u0000 \u0000 <p>The index case is a 2-year-old female who developed a right thoracic tumor that was surgically removed and treated with multi-agent chemotherapy. The patient is free from recurrence, although it was 9 years after the diagnosis when she developed a thyroid tumor. We performed in vitro cultivation of the isolated neoplastic cells from the tumor, cytogenetic findings and molecular analysis, and tetrazolium colorimetric assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>The histology was consistent with PPB. Serial passage of cultivation produced a continuously growing cell line, KCMC-PPB-1. Conventional cytogenetic analysis of the established cell line revealed complex numerical and structural chromosomal abnormalities, including add(17)(p11). Mutation analysis on the cultured cells revealed amino-acid substitution mutation on exon 4 of <i>TP53</i> (NM_001276760.3:c.212_213delTG; NP_001263689.1:p.Leu72ArgfsTer37) and compound heterozygous mutations of <i>DICER1</i> (NM_177438.3:c. 4910C&gt;A; NP_803187.1:Ser1637* and NM_177438.3:c. 5114A&gt;T; NP_803187.1:Glu1705Val). The cultivated cells demonstrated vulnerability to bortezomib on cytotoxicity assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our KCMC-PPB-1 is the first genuine, molecularly characterized PPB cell line. The cell line is transplantable to nu/nu mice; therefore, it is suitable for a preclinical model for new drug development. The cytotoxicity assay demonstrated that bortezomib is active in the current PPB model.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 10","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MYH9::LTK Fusion in a Pediatric Acral Soft Tissue Spindle Cell Neoplasm","authors":"Larissa V. Furtado,&nbsp;Ana C. Polanco,&nbsp;Zonggao Shi,&nbsp;Soad Fuentes-Alabi,&nbsp;Roxana Martinez,&nbsp;Alberto Pappo,&nbsp;Teresa Santiago","doi":"10.1002/gcc.23277","DOIUrl":"https://doi.org/10.1002/gcc.23277","url":null,"abstract":"","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 10","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142429985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RUNX1::MIR99AHG Chimera in Acute Myeloid Leukemia","authors":"Kristin Andersen,&nbsp;Geir E. Tjønnfjord,&nbsp;L. Frode Ramslien,&nbsp;Ioannis Panagopoulos","doi":"10.1002/gcc.23272","DOIUrl":"https://doi.org/10.1002/gcc.23272","url":null,"abstract":"<p><i>RUNX1</i> fuses with over 70 different partner genes in hematological neoplasms. While common <i>RUNX1</i> chimeras have been extensively studied and their prognosis is well established, our current understanding of less common <i>RUNX1</i> chimeras is limited. Here, we present a case of acute myeloid leukemia (AML) with a rare <i>RUNX1</i> chimera. Bone marrow cells obtained at diagnosis from a 71-year-old patient diagnosed with AML-M5 were studied using G-banding, fluorescence in situ hybridization, array comparative genomic hybridization, RNA sequencing, PCR, and Sanger sequencing. Combined findings from the abovementioned assays suggested three cytogenetic clones: one with a normal karyotype, one with inv(21)(q21q22), and one with two inv(21)(q21q22). The molecular analysis revealed the fusion of <i>RUNX1</i> with <i>MIR99AHG</i> (at 21q21.1), further supporting the presence of an inv(21)(q21q22). The present case is the third reported AML harboring a <i>RUNX1::MIR99AHG</i> chimera. Similar to the two previously described AML patients, our case also had an <i>FLT3</i> aberration.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.23272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Reclassification of Genetic Variants in South African Populations with Breast Cancer","authors":"Tabitha S. Osler,&nbsp;Jean-Tristan Brandenburg,&nbsp;Mardelle Schoeman,&nbsp;Wenlong Carl Chen,&nbsp;Michael F. Urban,&nbsp;Christopher G. Mathew","doi":"10.1002/gcc.23275","DOIUrl":"https://doi.org/10.1002/gcc.23275","url":null,"abstract":"<p>Concurrent testing of numerous genes for hereditary breast cancer (BC) is available but can result in management difficulties. We evaluated use of an expanded BC gene panel in women of diverse South African ancestries and assessed use of African genomic data to reclassify variants of uncertain significance (VUS). A total of 331 women of White, Black African, or Mixed Ancestry with BC had a 9-gene panel test, with an additional 75 genes tested in those without a pathogenic/likely pathogenic (P/LP) variant. The proportion of VUS reclassified using ClinGen gene-specific allele frequency (AF) thresholds or an AF &gt; 0.001 in nonguidelines genes in African genomic data was determined. The 9-gene panel identified 58 P/LP variants, but only two of the P/LP variants detected using the 75-gene panel were in confirmed BC genes, resulting in a total of 60 (18.1%) in all participants. P/LP variant prevalence was similar across ancestry groups, but VUS prevalence was higher in Black African and Mixed Ancestry than in White participants. In total, 611 VUS were detected, representing 324 distinct variants. 10.8% (9/83) of VUS met ClinGen AF thresholds in genomic data while 10.8% (26/240) in nonguideline genes had an AF &gt; 0.001. Overall, 27.0% of VUS occurrences could potentially be reclassified using African genomic data. Thus, expanding the gene panel yielded few clinically actionable variants but many VUS, particularly in participants of Black African and Mixed Ancestry. However, use of African genomic data has the potential to reclassify a significant proportion of VUS.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.23275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"17p13 (TP53) Deletions Are Associated With an Aggressive Phenotype but Unrelated to Patient Prognosis in Urothelial Bladder Carcinomas","authors":"Martina Kluth,&nbsp;Melanie Hitzschke,&nbsp;Kira Furlano,&nbsp;Henning Plage,&nbsp;Sebastian Hofbauer,&nbsp;Sarah Weinberger,&nbsp;Bernhard Ralla,&nbsp;Annika Fendler,&nbsp;Michela de Martino,&nbsp;Florian Roßner,&nbsp;Simon Schallenberg,&nbsp;Sefer Elezkurtaj,&nbsp;Maximilian Lennartz,&nbsp;Andreas H. Marx,&nbsp;Henrik Samtleben,&nbsp;Margit Fisch,&nbsp;Michael Rink,&nbsp;Marcin Slojewski,&nbsp;Krystian Kaczmarek,&nbsp;Thorsten Ecke,&nbsp;Stefan Koch,&nbsp;Nico Adamini,&nbsp;Joachim Weischenfeldt,&nbsp;Tobias Klatte,&nbsp;Sarah Minner,&nbsp;Ronald Simon,&nbsp;Guido Sauter,&nbsp;Thorsten Schlomm,&nbsp;David Horst,&nbsp;Henrik Zecha","doi":"10.1002/gcc.23271","DOIUrl":"https://doi.org/10.1002/gcc.23271","url":null,"abstract":"<p>17p13 deletions including <i>TP53</i> and other genes represent a common cause for reduced/lost p53 function in tumor cells. In this study, we analyzed the impact of 17p13 (<i>TP53</i>) deletions and p53 expression on tumor aggressiveness and patient prognosis in urothelial carcinoma. The 17p13 copy number status was analyzed by fluorescence in situ hybridization (FISH) on more than 2700 urothelial bladder carcinomas in a tissue microarray format. 17p13 deletion data were compared to p53 expression data measured by immunohistochemistry (IHC) in a previous study. Different types of p53 alterations were compared with tumor phenotype and clinical outcome data. Deletions of 17p13 occurred in 23% of 2185 analyzable carcinomas. The fraction of tumors with 17p13 deletions increased from pTa G2 low (9%) to pTa G3 (24%, <i>p</i> &lt; 0.0001). In muscle-invasive carcinomas, 17p13 deletions were associated with advanced pT stage (<i>p</i> = 0.0246), but unrelated to patient prognosis (<i>p</i> &gt; 0.5). 17p13 deletions were significantly related to p53 immunostaining (<i>p</i> = 0.0375). 17p13 deletions were most common in tumors with complete lack of p53 staining (31%), which supports the concept that many of these tumors have a complete loss of p53 function (p53 null phenotype). 17p13 deletions were also increased in tumors with high p53 staining (25%). In conclusion, 17p13 deletions were most commonly seen in p53 negative cancers, supporting their role as a cause for the p53 null phenotype in urothelial cancer. The association of 17p13 deletions with high grade and advanced pT stage may reflect increasing genomic instability going along with stage and grade progression.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.23271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spindle Cell Rhabdomyosarcoma of the Prostate With ZFP64::NCOA2 Fusion","authors":"Azfar Neyaz,&nbsp;Alessandro Furlan,&nbsp;Arivarasan Karunamurthy,&nbsp;Ivy John","doi":"10.1002/gcc.23274","DOIUrl":"https://doi.org/10.1002/gcc.23274","url":null,"abstract":"","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and Therapeutic Implications of a FUS::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma","authors":"Veronika Csizmok,&nbsp;Cameron J. Grisdale,&nbsp;Laura M. Williamson,&nbsp;Howard J. Lim,&nbsp;Lawrence Lee,&nbsp;Daniel J. Renouf,&nbsp;Steven J. M. Jones,&nbsp;Marco A. Marra,&nbsp;Janessa Laskin,&nbsp;Alannah Smrke","doi":"10.1002/gcc.23259","DOIUrl":"https://doi.org/10.1002/gcc.23259","url":null,"abstract":"<p>The identification of gene fusions in rare sarcoma subtypes can have diagnostic, prognostic, and therapeutic impacts for advanced cancer patients. Here, we present a case of a 31-year-old male with a lytic lesion of the left mandible initially diagnosed as an osteosarcoma but found to have a TFCP2 fusion and ALK alteration, redefining the diagnosis and providing rationale for a novel treatment strategy. Histologically, the tumor displayed hypercellular, spindled to epithelioid neoplasm and nuclear pleomorphism, while immunohistochemistry showed diffuse SATB2 and focal desmin staining. Whole genome and transcriptome analysis revealed a <i>FUS::TFCP2</i> fusion, the defining alteration of a rare molecularly characterized subtype of soft tissue sarcoma termed intraosseous rhabdomyosarcoma. An internal ALK deletion and extremely high ALK RNA expression were also identified, suggesting potential benefit of an ALK inhibitor. This patient displayed a rapid and dramatic clinical and radiographic response to an ALK inhibitor, alectinib. Unfortunately, the response was short-lived, likely due to the advanced stage and aggressiveness of the disease. This report describes genome and transcriptome characterization of an intraosseous rhabdomyosarcoma, few of which exist in the literature, as well as providing evidence that inhibition of ALK may be a rational treatment strategy for patients with this exceedingly rare soft tissue sarcoma subtype characterized by TFCP2 fusions and ALK activation.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.23259","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Juvenile Nasopharyngeal Angiofibromas via Whole-Exome Sequencing","authors":"Kiran Kumari,&nbsp;Shariya Afroj,&nbsp;Deeksha Madhry,&nbsp;Yash Verma,&nbsp;Arvind K. Kairo,&nbsp;Alok Thakar,&nbsp;Kapil Sikka,&nbsp;Hitesh Verma,&nbsp;Bhupendra Verma","doi":"10.1002/gcc.23265","DOIUrl":"https://doi.org/10.1002/gcc.23265","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The molecular basis and mechanisms of juvenile nasopharyngeal angiofibromas (JNA) pathogenesis are still unknown. Despite being a rare and benign neoplasm, JNA is a locally aggressive and potentially destructive head and neck neoplasm, typically found in young males. The advancement of genome technologies and analytical tools has provided an unparalleled opportunity to explore the intricacy of JNA. The present study provides the first evidence of the involvement of Y-chromosome genes in JNA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 13 JNA patients at an advanced disease stage and five age-matched male controls were registered for this study. Whole-exome sequencing (WES) analysis was conducted followed by functional analysis to understand the molecular mechanism of the JNA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>WES analysis revealed a high prevalence of mutations in 14 genes within the protein-coding, male-specific region of the Y-chromosome of young males (mean age: 13.8 ± 2.4) with JNA. These mutations, occurring at 28 distinct positions, were characterized as moderate to high impact and were prevalent in nine JNA patients but not in the control group. The most frequently mutated genes were USP9Y and UTY, followed by KDM5D, DDX3Y, and TSPY4. The expression of USP9Y, UTY, and DDX3Y was found to be co-modulated, implying their coordinated regulation as a complex. Furthermore, somatic mutations were detected in genes previously linked to JNA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The wide array of genetic mutations in the Y-chromosome male-specific region, along with the somatic alterations identified in JNA, provides novel insights into JNA pathophysiology.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Level BCR::ABL1 Transcript at Diagnosis in Childhood Leukemia: A 10-Year Single Institution Study","authors":"Lucy E. Cain,&nbsp;Oksana Mirochnik,&nbsp;Michael M. Stevens,&nbsp;Stewart J. Kellie,&nbsp;Bhavna Padhye,&nbsp;Steven J. Keogh,&nbsp;Dinisha Govender,&nbsp;Jessica Ryan,&nbsp;Luciano Dalla-Pozza,&nbsp;Caroline M. Bateman","doi":"10.1002/gcc.23269","DOIUrl":"https://doi.org/10.1002/gcc.23269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is a high risk form of ALL associated with dismal outcomes in the pre-tyrosine kinase inhibitor (TKI) era. Addition of a TKI to chemotherapy improves outcomes. Therefore, testing for the presence of the Philadelphia chromosome by at least two methods at the time of diagnosis is critical. Diagnostic testing may include karyotype, fluorescent in situ hybridisation (FISH), and RT-PCR for the <i>BCR</i>::<i>ABL1</i> transcript. The significance of low-level <i>BCR</i>::<i>ABL1</i> transcript by RT-PCR in the absence of the Philadelphia chromosome on karyotype or by FISH is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a retrospective review of children diagnosed with acute leukemia at our institution from 2010 to 2020. Those positive for the <i>BCR</i>::<i>ABL1</i> transcript by qualitative RT-PCR, and negative for t(9;22) by karyotype or FISH were analyzed for demographics, cytogenetic and molecular features at diagnosis and relapse, treatment and outcomes. The Kaplan–Meier method was used to estimate event-free and overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-seven of 306 (15%) patients with Ph- ALL had low-level <i>BCR</i>::<i>ABL1</i> detected by RT-PCR. Most (77%) had B-cell ALL. The e1a2 transcript was detected most frequently, in 43 (91%) patients. <i>BCR</i>::<i>ABL1</i> was quantifiable in 12/43 (28%) patients, with a median of 0.0008% (range 0.0003–0.095%). Seven patients (15%) relapsed. No patient with low-level <i>BCR</i>::<i>ABL1</i> at diagnosis developed Ph + ALL at relapse. There was no difference in 5-year event-free (77% versus 81%, <i>p</i> = 0.407) or overall survival (86% versus 91%, <i>p</i> = 0.3) between children with low-level <i>BCR</i>::<i>ABL1</i> (<i>n</i> = 47) and those without (<i>n</i> = 259).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>BCR</i>::<i>ABL1</i> low-level positivity in children with newly diagnosed Ph- ALL is a relatively common finding and did not adversely affect outcome for patients treated using a contemporary risk-adapted approach.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analyses of Somatic Copy Number Alterations and Mutations Based on the Adenoma–Carcinoma Sequence","authors":"Tamotsu Sugai,&nbsp;Mitsumasa Osakabe,&nbsp;Noriyuki Uesugi,&nbsp;Wataru Habano,&nbsp;Naoki Yanagawa,&nbsp;Hiromu Suzuki","doi":"10.1002/gcc.23267","DOIUrl":"https://doi.org/10.1002/gcc.23267","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Identifying molecular alterations in the adenoma and carcinoma components within the same tumor would greatly contribute to understanding the neoplastic progression of early colorectal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We examined somatic copy number alterations (SCNAs) and mutations involved in the adenoma and carcinoma components obtained from the same tumor in 46 cases of microsatellite-stable carcinoma in adenoma, using a genome-wide SNP array and gene mutation panel. In addition, we also performed hierarchical clustering to determine the SCNA frequencies in the tumors, resulting in stratification of the samples into two subgroups according to SCNA frequency. Subgroup 1 was characterized by multiple SCNAs and carcinoma components exclusively, while Subgroup 2 was characterized by a low frequency of SCNAs and both the adenoma and carcinoma components. The numbers of total genes and genes with gains were higher in the carcinoma than adenoma components. The three most frequent gains in both components were located at 1p36.33–1q44, 2p25.3–2q37.3, and 3p26.3–3q29. However, no candidate genes mapped to these regions. <i>APC</i> and <i>KRAS</i> mutations were common in both components, whereas the frequency of <i>TP53</i> mutations was statistically higher in the carcinoma than adenoma component. However, <i>TP53</i> mutations were not correlated with SCNA frequency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We suggest that considerable SCNAs and <i>TP53</i> mutations are required for progression from adenoma to carcinoma within the same intramucosal neoplastic lesion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 9","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.23267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}